ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1903

Assessment of Subclinical Atherosclerosis in Patients with Systemic Sclerosis: Results from a Multicentric Cohort

Codrina Ancuta1,2, Codruta Belibou3, Cristina Pomirleanu1,4, Carina Mihai5, Ioan Ancuta5, Patricia E. Carreira6, Jose Luis Rosales Alexander7, Juan José Alegre8, Valeria Riccieri9, Maria J. Salvador10 and Rodica Chirieac4, 1Rheumatology, Gr.T.Popa University of Medicine and Pharmacy, Iasi, Romania, 2Rheumatology 2, Clinical Rehablitation Hospital, Iasi, Romania, 3Research Department, Clinical Rehabilitation Hospital, Iasi, Romania, 4Rheumatology 2, Clinical Rehabilitation Hospital, Iasi, Romania, 5Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 6Multidisciplinary Pulmonary Hypertension Unit. Hospital Universitario 12 de Octubre, Madrid, Spain, 7Rheumatology, Hospiten Health Network, Tenerife, Spain, 8Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 9Cattedra di Reumatologia, Dip Clinica e Terapia Medica, Sapienza Università di Roma, Roma, Italy, 10Rheumatology, Centro Hospitalar e Universitário de Coimbra - Hospitais da Universidade de Coimbra, EPE, Coimbra, Portugal

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, Biomarkers and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Although numerous studies have reported different findings on subclinical and definite atherosclerosis (AS) in autoimmune rheumatic diseases, data in systemic sclerosis (SSc) are still challenging. The main objectives of our study were to assess surrogate biomarkers of subclinical AS as measured by carotid ultrasound and to evaluate potential relation with different cardiovascular risk factor in different settings of SSc.

Methods: We conducted a cross-sectional prospective study in 6 European EUSTAR (European Scleroderma Trials and Research) centers on 301 consecutive SSs patients enrolled in the SSAS (Early Accelerated Atherosclerosis in Systemic Sclerosis) cohort (88.3% women, 71.4% limited skin involvement SSc). Traditional (smoking, hypertension, diabetes, abnormal lipid pattern, familial history of cardiovascular disease) and non-traditional cardio-vascular risk factors (disease activity and severity, hsCRP, immune profile, glucocorticoids, synthetic immunosuppressives) as well as surrogate biomarkers for subclinical AS (carotid scanning measuring common carotid arteries intima-media thickness, cIMT, and plaques in common, internal and external carotid) were collected in all patients as a single point data. Subgroup analysis based on skin extent and serology profile was further performed using SPSS.  

Results: We reported an average of 0.65±0.14 mm  (0.43-1.20) for cIMT, with a slight tendency of higher values in diffuse cutaneous (dc) SSc subgroup as compared with limited cutaneous (lc) SSc with no statistically significance (p>0.05). In addition we identified several statistically significant correlations between cIMT and age, systolic blood pressure, abnormal lipid profile (cholesterol, total chol/HDL-col, triglycerides), disease duration, activity and severity (EUSTAR score, MEDSGER severity scale) (p<0.05), maintained in subgroup analysis. However, no significant relation with the glucocorticoid and immunosuppressive intake was demonstrated. At least one carotid plaque causing no or non-significant stenosis was observed in up to one third of cases, particularly in dcSSc, with age, smoking and hypertension independently associated with AS plaques, as well as the cumulative steroid dose (p<0.05). Although subgroup analysis suggested a higher values for AS parameters and risk factors in dcSSc as well as anti-SCL and ACA-positive patients, data were not statistically significant (p>0.05). Actual results confirm interim analysis data.

Conclusion: SSc is associated with an increased risk of developing subclinical AS, although early AS is not a hallmark of the disease. Age, dyslipidemia and hypertension as well as disease duration, activity and severity are listed as potential risk factors for AS particularly in dcSSc subtype.


Disclosure: C. Ancuta, None; C. Belibou, None; C. Pomirleanu, None; C. Mihai, None; I. Ancuta, None; P. E. Carreira, None; J. L. Rosales Alexander, None; J. J. Alegre, None; V. Riccieri, None; M. J. Salvador, None; R. Chirieac, None.

To cite this abstract in AMA style:

Ancuta C, Belibou C, Pomirleanu C, Mihai C, Ancuta I, Carreira PE, Rosales Alexander JL, Alegre JJ, Riccieri V, Salvador MJ, Chirieac R. Assessment of Subclinical Atherosclerosis in Patients with Systemic Sclerosis: Results from a Multicentric Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessment-of-subclinical-atherosclerosis-in-patients-with-systemic-sclerosis-results-from-a-multicentric-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-subclinical-atherosclerosis-in-patients-with-systemic-sclerosis-results-from-a-multicentric-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology